Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.

Abstract

Psoriasis is a chronic inflammatory skin condition, characterized by T-helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)-12 and IL-23, consequently inhibiting T-cell differentiation along both Th1 and Th17 pathways. This is a report of two patients who developed psoriatic arthritis during ustekinumab treatment for psoriasis. Neither patient had a personal or family history of arthritis.

• Authors: A de Souza, T Ali-Shaw, S M Reddy, D Fiorentino, B E Strober
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 168 Issue 1 Pg. 210-2 (Jan 2013) ISSN: 1365-2133 [Electronic] England
• PMID: 23278559 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Chemical References

• Antibodies, Monoclonal, Humanized
• Dermatologic Agents
• Ustekinumab

Topics

• Adult
• Antibodies, Monoclonal, Humanized (adverse effects)
• Arthritis, Psoriatic (chemically induced)
• Dermatologic Agents (adverse effects)
• Humans
• Male
• Psoriasis (drug therapy)
• Ustekinumab